Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases
Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital…
Q&A with Alice Brown
July 2024 Can you tell us a bit about yourself and your background and what…
Purespring Therapeutics presents preclinical data at the 61st ERA Congress
Data establishes the potential of AAV gene therapy to deliver transgenes to the podocyte to…
Q&A with Fredrik Erlandsson
March 2024 When and how did you first get involved with Purespring? Purespring caught my…
Purespring appoints Fredrik Erlandsson as Chief Medical Officer and Peter Mulcahy as Chief People Officer
Appointments of Fredrik and Peter complete build-out of senior team. London— 6 September 2023 Purespring…
Q&A with Julian Hanak
August 2023 When and how did you first get involved with Purespring? Before joining Purespring,…
Purespring Therapeutics appoints Sachin Kelkar as CFO following appointment of Julian Hanak as CEO
Senior leadership team strengthened as Purespring prepares kidney gene therapy programmes for clinical development. London—…
World Kidney Day 2023: Transforming Kidney Disease through Podocyte Gene Therapy
World Kidney Day 2023: Transforming Kidney Disease through Podocyte Gene Therapy Authors: Pille Harrison, Moin…
Purespring Therapeutics strengthens scientific leadership with the appointment of Alice Brown as Chief Scientific Officer
Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases,…
Purespring Therapeutics Expands Senior Team with Key Appointments
Appointments include Dr Pille Harrison as VP of Clinical Development, Dr Aoife Waters as Medical…